Recombinant interferon-β-1a: A review of its therapeutic efficacy in relapsing-remitting multiple sclerosis

BioDrugs

Volumn 10, Issue 6, 1998, Pages 471-494

  Wagstaff, Antona J ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BETA1A INTERFERON; NEUTRALIZING ANTIBODY; STEROID;

ANTIBODY PRODUCTION; BLOOD TOXICITY; DISEASE ACTIVITY; DOSE CALCULATION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; FLU LIKE SYNDROME; HUMAN; IMMUNOMODULATION; INTRAMUSCULAR DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; STEROID THERAPY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032443218     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199810060-00005     Document Type: Review

References (79)

1. Rudick RA, Cohen JA, Weinstock-Guttman B, et al. Management of multiple sclerosis. N Engl J Med 1997 Nov 27; 337 (22): 1604-11
2. Brod SA, Lindsey JW, Wolinsky JS. Multiple sclerosis: clinical presentation, diagnosis and treatment. Am Fam Physician 1996 Sep 15; 54: 1301-11
3. Lublin F-D, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996 April; 46: 907-11
4. Paty DW, Blumhardt LD, PRISMS Study Group. High-dose subcutaneous interferon β-1a is efficacious in transitional multiple sclerosis, a group at high risk of progression in disability [poster], 123rd Annual meeting of the American Neurological Association (ANA), Montréal, Canada; 18-21 Oct 1998
5. Andersson P-B, Waubant E, Goodkin DE. How should we proceed with disease-modifying treatments tor multiple sclerosis? Lancet 1997 Mar 1; 349: 586-7
6. Landtblom A-M. Exposure to organic solvents and multiple sclerosis. Neurology 1997 Aug; 49 (Suppl. 2): S70-4
7. Poser CM. The role of trauma in the pathogenesis of multiple sclerosis: a review. Clin Neurol Neurosurg 1994 May; 96: 103-10
8. Revel M, Kalinka P. Chapter 29. Glycosylated interferon-beta in multiple sclerosis. In: Abramsky O, Ovadia H, editors. Frontiers in multiple sclerosis: clinical research and therapy. London: Martin Dunitz Ltd. 1997: 243-54
9. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 1996 May 3; 85: 299-302
10. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, et al. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995 Jan; 37: 7-15
11. McGeer EG, McGeer PL. Inflammatory cytokines in the CNS: possible role in the pathogenesis of neurodegenerative disorders and therapeutic implications. CNS Drugs 1997 Mar; 7: 214-28
12. Kinkel RP, Goodkin DE. Immunotherapy for multiple sclerosis. A review of the clinical experience. Clin Immunother 1994 Feb; 1: 117-34
13. Runkel L, Meier W, Pepinsky RB, et al. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (ILN-β). Pharm Res 1998; 15 (4): 641-9
14. Ares Serono. Product comparability testing. 1998 (Data on file)
15. Holliday SM, Benfield P. Interferon-β-1a: a review of its pharmacological properties and therapeutic potential in multiple sclerosis. Biodrugs 1997 Oct; 8: 317-30
16. Alam J, Goelz S, Rioux P, et al. Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN-β-1a) products administered intramuscularly in healthy male and female volunteers. Pharm Res 1997 Apr; 14: 546-9
17. Salmon P, Le Cotonnee JY, Galazka A, et al. Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy male volunteers. J Interferon Cyto Res 1996 Oct; 16: 759-64
18. Munafo A, Trinchard-Lugan I, Nguyen TXQ, et al. Comparative bioavailability of human interferon beta following single-dose subcutaneous and intramuscular administration of recombinant human interferon beta-1a [abstract no. BF2974]. In: International Business Communications (IBC) 5th Annual Conference on Multiple Sclerosis. Cambridge, MA, USA: 16-17 Jun, 1997
19. Ares Serono International SA. Canadian package insert. March 1998
20. Arky R. Physicians Desk Reference: 697-700. 52nd ed. Montvale, NJ: Medical Economics Co Inc, 1998
21. Liberati AM, Horisberger MA, Palmisano L, et al. Double-blind randomized phase I study on the clinical tolerance and biological effects of natural and recombinant interferon-beta. J Interferon Res 1992; 12 (5): 329-36
22. Liberati AM, Garofani P, De Angelis V. et al. Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-β given intravenously. J Interferon Res 1994; 14 (2): 61-9
23. Munafo A, Spertini F, Rothuisen L, et al. Pharmacodynamic response to r-hIFN β 1a administered subcutaneously once-a-week (QW) or three-times-a-week (TIW), over one month. ECTRIMS 97 13th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Istanbul, 2-5 November, 1997 [abstract no. P226]. Multiple Sclerosis 1997 Nov; 3 (5): 343
24. Munafo A, Rothuizen L. Spertini F, et al. Pharmacodynamic response to IFN β-1a administered subcutaneously once a week (QW) or three times a week (TIW) over 1 month [Poster]. In: 13th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Istanbul: 2-5 Nov, 1997
25. Becker CC, Gidal BE, Fleming JO. Immunotherapy in multiple sclerosis, part 2. Am J Health System Pharm 1995 Oct 1; 52: 2105-20
26. Rudick RA, Ransohoff RM, Lee J-C, et al. In vivo effects of Interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 1998; 50: 1294-300
27. Arnason BGW, Reder AT. Interferons and multiple sclerosis. Clin Neuropharmacol 1994 Dec; 17: 495-547
28. Munafo A, Trinchard-Lugan I, Nguyen TXQ, et al. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Eur Neurol 1998; 5 (2): 187-93
29. Buchwalder P-A, Buclin T, Trinchard A, et al. Pharmacokinetics and pharmacodynamics of interferon β-1a in healthy volunteers [Poster presented at 99th Annual meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), New Orleans, USA, 30 Mar-1 Apr 1998]
30. Eshkol A, Mascia M, Terlizzese MG, et al. Problems associated with potency determinations of beta interferons by in vitro bioassays. Ares Serono International SA, Study 8213/9122, 1998 (Data on file)
31. Buchwalder P-A, Buclin T, Trinchard I, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of interferon β-1a in healthy volunteers [abstract no. PI-117 (presented at the 99th annual meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), New Orleans, USA, 30 Mar-1 Apr 1998)]. Clin Pharmacol Ther 1998 Feb; 63: 166
32. Waubant EL, Goodkin DE. Assessing efficacy in clinical trials of treatments for multiple sclerosis: issues and controversy. CNS Drugs 1996 Dec; 6: 462-73
33. Becker CC, Gidal BE, Fleming JO. Immunotherapy in multiple sclerosis, part 1. Am J Health System Pharm 1995 Sep 15; 52: 1985-2000
34. Rudick R, Antel J, Confavreux C, et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 1997 Sep; 42: 379-82
35. Lublin FD, Reingold SC, National MSSUSAAC on CT of NA in MS. Guidelines for clinical trials of new therapeutic agents in multiple sclerosis. Relations between study investigators, advisors, and sponsors. Neurology 1997 Mar; 48: 572-4
36. Ebers GC. Treatment of multiple sclerosis. Lancet 1994 Jan 29; 343: 275-9
37. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983 Jan 27; 308 (4): 173-80
38. PRISMS (Prevention of Relapses and Disability by Interferon β-1a in Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998 Nov 7; 352: 1498-504
39. Ares Serono. A multicenter randomized, double-blind, placebo-controlled study of Rebif in patients with RRMS. Study no. GF 7999, 1998. (Data on file)
40. Pozzilli C, Bastianello S, Koudriavtseva T, et al. Magnetic resonance imaging changes with recombinant human interferon-β-1a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996 Sep; 61: 251-8
41. Koudriavtseva T, Fiorelli M, Bastianello S, et al. Profile of clinical responders to interferon-β-1a treatment in relapsing-remitting multiple sclerosis [abstract no. P207 (abstracts of the second congress of the European Federation of Neurological Sciences, Rome, Italy, 30 Oct-3 Nov 1996)]. European Journal of Neurology 1996 Oct; 3 Suppl.5: 90-1
42. Pozzilli C, Bastianello S, Koudriatseva T, et al. An open randomised trial with two different doses of recombinant interferon beta 1a in relapsing-remitting multiple sclerosis: clinical and MRI results at 24 months. Seventh meeting of the European Neurological Society: 14-18 June 1997; Rhodes, Greece [abstract no. 94]. J Neurology 1997 Jun; 244 Suppl. 3: S25
43. Koudriavtseva T, Pozzilli C, Fiorelli M, et al. Determinants of Gd-enhanced MRI response to IFN-β-1a treatment in relapsing-remitting multiple sclerosis. Multiple Sclerosis 1998; 98 (4): 403-7
44. R, subcutaneously in multiple sclerosis [Poster]. 13th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2-5 Nov 1997, Istanbul, Turkey: 1-4
45. Freedman MS. The Once Weekly Interferon for MS (OWIMS) Study Group. Dose-dependent clinical and MRI efficacy of interferon β-1a (Rebif) in multiple sclerosis [abstract no.9]. 123rd Annual Meeting of the American Neurological Association. Montréal, Canada; Oct 18-21 1998: 32
46. The Once-Weekly Interferon for MS (OWIMS) Study Group. Interferon β-1a in multiple sclerosis: dose-dependent clinical and MRI efficacy [poster]. 123rd Annual meeting of the American Neurological Association (ANA), Montréal, Canada; 18-21 Oct 1998
47. Liu C, Li Wan Po A, Blumhardt LD. "Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64: 726-9
48. Li D, Zhao G, Hyde R, et al. Comparison of proton density/T2 (PD/T2) and gadolinium-enhanced T1 (GD-M1) MRI in demonstrating a treatment effect and dose difference in PRISMS trial of interferon β1a (REBIF) [abstract no. P387 (presented at the 8th meeting of the European Neurological Society (ENS), Nice, France, Jun 6-10, 1998)]. J Neurology 1998; 245 (6/7): 457
49. Koudriavtseva T, Fiorelli M, Bastianello S, et al. Interferon-β1a in relapsing-remitting multiple sclerosis: frequency of responders [Abstract no. P117 (Abstracts of the 12th European Congress on Multiple Sclerosis; Copenhagen, Denmark, 26-28 Sep 1996)]. European Journal of Neurology 1996 Sep; 3 Suppl.4: 51-2
50. Gasperini C, Pozzilli C, Bastianello S, et al. Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis. Neurology 1998 Feb; 50: 403-6
51. 1a in relapsing-remitting multiple sclerosis. Acta Neurol Scand 1997 Dec; 96: 372-4
52. Antonelli G. In vivo development of antibody to interferons: an update to 1996. J Interferon Cyto Res 1997; 17 Suppl. 1: S39-46
53. Antonelli G, Bagnato F, Pozzilli C, et al. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-β1a. J Inteferon Cyto Res 1998; 18: 345-50
54. Abdul-Ahad AK, Galazka AR, Revel M, et al. Incidence of antibodies to interferon-β in patients treated with recombinant human interferon-β1a from mammalian cells. Cytokine Mol Ther 1997 Mar; 3: 27-32
55. Weinstock-Guttman B, Rudick RA. Prescribing recommendations for interferon-beta in multiple sclerosis. CNS Drugs 1997 Aug; 8: 102-12
56. Andersson P-B, Goodkin DE. Current pharmacologie treatment of multiple sclerosis symptoms. West J Med 1996 Nov; 165: 313-7
57. van Oosten BW, Truyen L, Barkhof F, et al. Multiple sclerosis therapy: a practical guide. Drugs 1995 Feb; 49: 200-12
58. Lea AP, Goa KL. Copolymer-I: a review of its pharmacological properties and therapeutic potential in multiple sclerosis. Clin Immunother 1996 Oct; 6: 319-31
59. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998 Mar; 50: 701-8
60. Goodkin DE. Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis. West J Med 1994 Sep; 161: 292-8
61. Clark W. Therapeutic advances: beta-interferon for multiple sclerosis. J Clin Pharm Ther 1996 Aug; 21: 195-9
62. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993 Apr; 43: 655-61
63. Yudkin PL, Ellison GW, Ghezzi A, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991; 338: 1051-5
64. Confavreux C, Saddler P, Grimaud J, et al. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 1996 Jun; 46: 1607-12
65. Donoghue S. Drugs in development for the treatment of multiple sclerosis: antigen non-specific therapies. Expert Opin Invest Drug 1996 Oct; 5: 1349-57
66. Fricker J. Developing drugs for multiple sclerosis. Lancet 1996 Oct 12; 348: 1022
67. Schluep M, Bogousslavsky J. Emerging treatments in multiple sclerosis. Eur Neurol 1997; 38 (3): 216-21
68. Spack EG. Drugs in development for the treatment of multiple sclerosis: antigen-specific therapies. Expert Opin Invest Drug 1996 Oct; 5: 1331-48
69. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996 Mar; 39: 285-94
70. Summary basis for approval: Interferon beta-1a, Avonex@, Biogen, Inc. PLA: #95-0979; ELA: #95-0975
71. Khan OA, Dhib-Jalbut SS. Serum interferon β-1a (Avonex) levels following intramuscular injection in relapsing-remitting MS patients. Neurology 1998; 51: 738-42
72. Rudick RA, Jacobs L, Alam J, et al. Toxicity of recombinant intramuscular recombinant interferon-β-1a in multiple sclerosis patients [abstract]. Ann Neurol 1995 Aug; 38: 313
73. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 1998; 50: 1266-72
74. IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MR1 Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996 Oct; 47: 889-94
75. Rudge P, Miller D, Crimlisk H, et al. Does interferon beta cause initial exacerbation of multiple sclerosis? Lancet 1995 Mar 4; 345: 580
76. Calabresi PA, Stone LA, Bash CN, et al. Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. Neurology 1997 May; 48 (5): 1446-8
77. Khan OA, Hebel JR. Incidence of exacerbations in the first 90 days of treatment with recombinant human interferon β-1b in patients with relapsing-remitting multiple sclerosis. Ann Neurol 1998; 44: 138-9
78. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998 Jan 29; 338: 278-85
79. US MS society urges early drug treatment. Scrip 1998 Oct 23; 2381: 21